Business Context and Reporting Period
The filing is Brooks Automation, Inc.’s unaudited Form 10-Q for the quarter and six months ended March 31, 2018. The provided metadata identifies Azenta, Inc., but the filing itself identifies the registrant as Brooks Automation, Inc. The company operated through Brooks Semiconductor Solutions Group and Brooks Life Sciences, serving semiconductor capital equipment and life-sciences sample-management markets.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2018 | Prior Year | Six Months Ended March 31, 2018 | Prior Year |
|---|---|---|---|---|
| Revenue | $207.3 million | $169.3 million | $396.6 million | $329.3 million |
| Gross profit | $84.2 million | $64.5 million | $159.4 million | $121.5 million |
| Gross margin | 40.6% | 38.1% | 40.2% | 36.9% |
| Operating income | $23.8 million | $14.8 million | $44.7 million | $28.0 million |
| Net income | $67.0 million | $14.0 million | $83.5 million | $27.9 million |
| Diluted EPS | $0.95 | $0.20 | $1.18 | $0.40 |
| Operating cash flow | Not separately provided | Not separately provided | $23.4 million | $43.3 million |
- Revenue increased 22% in the quarter and 20% for the six-month period. Semiconductor Solutions revenue increased 18% and 15%, respectively; Life Sciences revenue increased 40% and 41%, respectively.
- Operating expenses rose to $60.4 million for the quarter and $114.8 million for the six months, primarily from higher employee costs, stock-based compensation, acquisition-related expenses, professional services and research and development.
- The quarterly effective tax result was materially affected by a $46.2 million reversal of a U.S. deferred-tax valuation allowance. Income tax benefits were $43.9 million for the quarter and $41.0 million for the six months.
- Cash, cash equivalents and marketable securities totaled $245.2 million at March 31, 2018, compared with $104.3 million at September 30, 2017.
- Total debt consisted primarily of a $199.5 million senior secured term-loan principal balance, net of $2.6 million in deferred financing costs. The term loan matures October 4, 2024 and had a weighted-average stated interest rate of approximately 4% during the six months.
- The company had no revolving-line borrowings and approximately $47.0 million of borrowing availability under its $75.0 million revolving facility.
- Inventory purchase commitments were $163.7 million, and letters of credit outstanding were approximately $2.6 million.
Material Changes Versus the Prior Comparable Period
- Gross margin expanded by 2.5 percentage points for the quarter and 3.3 percentage points for the six months, driven mainly by favorable mix, volume leverage, lower warranty costs and lower material costs in Semiconductor Solutions.
- Operating income increased 61% for the quarter and 60% for the six months despite higher operating expenses.
- Net income increased substantially, primarily because of the deferred-tax valuation allowance reversal; the improvement does not represent a comparable operating earnings increase.
- Operating cash flow declined to $23.4 million from $43.3 million, reflecting working-capital uses from higher receivables, inventories and prepaid assets.
- Investing cash outflows increased to $119.9 million from $10.7 million, including $65.0 million for acquisitions and $49.6 million for marketable securities purchases.
- Financing activities provided $184.0 million, principally from the October 2017 term loan, compared with a $13.0 million use of cash in the prior-year period.
- On October 5, 2017, the company acquired 4titude Limited for approximately $65.1 million, adding $7.8 million of six-month revenue but also acquisition-related amortization, inventory step-up and transaction costs.
Guidance, Outlook, Risks and Unusual Items
- No specific quantitative revenue or earnings guidance is provided in the filing. Management expects semiconductor demand to remain cyclical and identifies life-sciences sample management as a growth opportunity.
- Management stated that existing liquidity, operating cash flow, marketable securities and financing access should fund planned operations, capital expenditures, debt service and acquisitions for the next twelve months, while noting that longer-term liquidity is difficult to predict.
- The variable-rate term loan exposes the company to higher interest expense if LIBOR, federal funds or prime rates increase. A hypothetical 100-basis-point rate change would have affected six-month interest expense by approximately $0.5 million.
- Foreign-currency exposure remains material. The company recorded six-month foreign-currency losses of $2.5 million, and a hypothetical 10% exchange-rate change was estimated to affect six-month net income by approximately $2.1 million.
- Tax accounting remains subject to estimates under the Tax Cuts and Jobs Act. The estimated $5.2 million toll charge on accumulated foreign earnings was provisional, and the company had not recorded a current tax provision because tax attributes offset the estimated liability.
- The company expects future adoption of new revenue-recognition, lease and credit-loss standards. Revenue recognition may change for certain life-sciences percentage-of-completion arrangements and licenses.
- Subsequent to quarter-end, the company acquired approximately 93% of Tec-Sem Group AG for $11.3 million and acquired BioSpeciMan Corporation for $4.8 million. Purchase accounting for both transactions was incomplete at the filing date.
- Legal proceedings arise in the ordinary course of business. Management did not believe any then-pending matter would have a material adverse effect, but outcomes remain inherently uncertain.
- Management reported effective disclosure controls and procedures and no material change in internal control over financial reporting.
Investor Verification Priorities
- Verify the registrant identity because the filing text is for Brooks Automation, Inc., while the request metadata names Azenta, Inc.
- Separate the $46.2 million tax valuation-allowance reversal from recurring operating performance when assessing earnings quality.
- Assess whether the improvement in gross margin is sustainable after normalizing for acquisition accounting, amortization and product mix.
- Review the term loan’s variable-rate exposure, required amortization, excess-cash-flow provisions and secured status.
- Monitor working-capital trends, particularly receivables, inventories and prepaid assets, given the decline in operating cash conversion.
- Evaluate acquisition integration, goodwill of $275.2 million and intangible assets of $102.2 million for impairment risk.
- Consider semiconductor cyclicality, customer concentration and foreign-currency exposure; one customer represented approximately 12% of quarterly and six-month revenue.